Lansoprazole — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for GERD (Gastroesophageal Reflux Disease)

• Esomeprazole
• Famotidine
• Omeprazole
• Pantoprazole
• Ranitidine

Other medications in Gastrointestinal

• Loperamide
• Mesalamine
• Sucralfate
• Azathioprine
• Dapsone
• Dicyclomine
• Hyoscyamine

About Lansoprazole

Lansoprazole is a widely prescribed medication known for effectively managing conditions caused by excess stomach acid, such as heartburn and GERD. At TheDrugClub, we believe essential medications like lansoprazole should be affordable and accessible.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Lansoprazole is approved for (FDA label)

Lansoprazole delayed-release orally disintegrating tablets are proton pump inhibitors (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)‑-associated gastric ulcer in adults. (1.5) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. (1.7) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. (1.8) • Maintenance of healing of EE in adults. (1.9) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. (1.10) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies (14.1) ]. 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release orally disintegrating tablets /amoxicillin/clarithromycin Lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori.

Source: Read the full FDA label on DailyMed. Label effective date: August 24, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lansoprazole (FDA label)

• 15 mg tablets are white to yellowish white uncoated tablets with orange to dark brown speckles, debossed with ‘J’ on one side and ‘71’ on the other side of the tablet. • 30 mg tablets are white to yellowish white uncoated tablets with orange to dark brown speckles, debossed with ‘J’ on one side and ‘72’ on the other side of the tablet. • Delayed-release orally disintegrating tablets: 15 mg and 30 mg. (3)

Source: FDA prescribing information (DailyMed). Set ID: 7daa1721-f92b-4096-b19e-4d27fc8acb51. Label effective date: August 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lansoprazole (FDA label)

The following serious adverse reactions are described below and elsewhere in labeling: • Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] • Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] • Bone Fracture [see Warnings and Precautions (5.4) ] • Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5) ] • Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.6) ] • Cyanocobalamin (Vitamin B12) Deficiency [see Warnings and Precautions (5.7) ] • Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.8) ] • Fundic Gland Polyps [see Warnings and Precautions (5.12) ] Most commonly reported adverse reactions (≥1%): diarrhea, abdominal pain, nausea and constipation. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 7daa1721-f92b-4096-b19e-4d27fc8acb51. Label effective date: August 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lansoprazole (FDA label)

• Lansoprazole delayed-release orally disintegrating tablets are contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2) , Adverse Reactions (6) ] . • Proton Pump Inhibitors (PPIs), including lansoprazole delayed-release orally disintegrating tablets, are contraindicated with rilpivirine-containing products [see Drug Interactions (7) ]. • For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with lansoprazole delayed-release orally disintegrating tablets, refer to the Contraindications section of their prescribing information. • Contraindicated in patients with known hypersensitivity to any component of the lansoprazole delayed-release orally disintegrating tablets formulation. ( 4 ) • Patients receiving rilpivirine-containing products. ( 4 , 7 )

Source: FDA prescribing information (DailyMed). Set ID: 7daa1721-f92b-4096-b19e-4d27fc8acb51. Label effective date: August 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lansoprazole (FDA label)

• Gastric Malignancy : In adults, symptomatic response with lansoprazole delayed-release orally disintegrating tablets does not preclude the presence of gastric malignancy.

Source: FDA prescribing information (DailyMed). Set ID: 7daa1721-f92b-4096-b19e-4d27fc8acb51. Label effective date: August 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lansoprazole (FDA label)

Tables 2 and 3 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with lansoprazole delayed-release orally disintegrating tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2. Clinically Relevant Interactions Affecting Drugs Coadministered with Lansoprazole Delayed-Release Orally Disintegrating Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance. • Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with lansoprazole may increase toxicity of the antiretroviral drugs.

Source: FDA prescribing information (DailyMed). Set ID: 7daa1721-f92b-4096-b19e-4d27fc8acb51. Label effective date: August 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.